• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

作者信息

Sadée W, Dagcioglu M, Schröder R

出版信息

J Pharmacol Exp Ther. 1973 Jun;185(3):686-95.

PMID:4712657
Abstract
摘要

相似文献

1
Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
J Pharmacol Exp Ther. 1973 Jun;185(3):686-95.
2
The effect of spironolactone and canrenone on the digoxin radioimmunoassay.
Res Commun Chem Pathol Pharmacol. 1974 Dec;9(4):787-90.
3
Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.通过一种新的高压液相色谱法测定血浆浓度，对螺内酯代谢物坎利酮的抗盐皮质激素作用进行重新评估。
Drug Metab Dispos. 1979 Mar-Apr;7(2):103-7.
4
Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.螺内酯和坎利酸钾在心脏和肝脏衰竭中的多剂量动力学
Eur J Clin Pharmacol. 1974;7(3):195-200. doi: 10.1007/BF00560381.
5
Spirolactones: clinical and pharmacologic studies.螺内酯：临床与药理学研究
Adv Nephrol Necker Hosp. 1977;7:199-215.
6
Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.螺内酯、坎利酮和坎利酸钾对牛和人肾上腺皮质线粒体中细胞色素P450以及11β-和18-羟化作用的影响。
Endocrinology. 1976 Oct;99(4):1097-106. doi: 10.1210/endo-99-4-1097.
7
Spironolactone and canrenoate-K: relative potency at steady state.螺内酯和坎利酸钾：稳态时的相对效价。
Clin Pharmacol Ther. 1977 May;21(5):602-9. doi: 10.1002/cpt1977215602.
8
Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.大鼠体内螺内酯向坎利酮的转化以及螺内酯和坎利酸钾的处置动力学
Naunyn Schmiedebergs Arch Pharmacol. 1974;283(3):303-18. doi: 10.1007/BF00499190.
9
Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.螺内酯、坎利酸钾及其共同代谢产物坎利酮对采用新型地高辛免疫分析法地高辛III测定血清地高辛的影响。
Ther Drug Monit. 2008 Dec;30(6):744-7. doi: 10.1097/FTD.0b013e31818b0e6a.
10
Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.雅培 ARCHITECT 临床化学和免疫分析系统：地高辛检测不受螺内酯、坎利酮及其常见代谢产物坎利酮的干扰。
Ther Drug Monit. 2011 Feb;33(1):128-31. doi: 10.1097/FTD.0b013e3181fd4c30.

引用本文的文献

1
Determination of serum concentrations of canrenone (active metabolite of spironolactone) in patients with heart failure with reduced ejection fraction: a cross-sectional study.射血分数降低的心力衰竭患者血清坎利酮（螺内酯的活性代谢产物）浓度的测定：一项横断面研究。
Pharmacol Rep. 2025 Aug 29. doi: 10.1007/s43440-025-00776-9.
2
Model-Informed Dose Optimization of Spironolactone in Neonates and Infants.新生儿和婴儿螺内酯的模型指导剂量优化
Pharmaceuticals (Basel). 2025 Mar 1;18(3):355. doi: 10.3390/ph18030355.
3
Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease.
内源性蟾毒配基、盐皮质激素受体拮抗剂与慢性肾脏病中的纤维化
Front Pharmacol. 2024 Sep 4;15:1431216. doi: 10.3389/fphar.2024.1431216. eCollection 2024.
4
Neuronal aldosterone elicits a distinct genomic response in pain signaling molecules contributing to inflammatory pain.神经元醛固酮在引起炎症性疼痛的痛觉信号分子中引发独特的基因组反应。
J Neuroinflammation. 2020 Jun 12;17(1):183. doi: 10.1186/s12974-020-01864-8.
5
Endogenous Bufadienolides, Fibrosis and Preeclampsia.内源性蟾蜍二烯羟酸内酯、纤维化与子痫前期
Cardiol Res Pract. 2019 Dec 12;2019:5019287. doi: 10.1155/2019/5019287. eCollection 2019.
6
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.盐皮质激素受体的30年：盐皮质激素受体拮抗剂：60年的研发历程
J Endocrinol. 2017 Jul;234(1):T125-T140. doi: 10.1530/JOE-16-0600.
7
Role of mineralocorticoid receptor antagonists in cardiovascular disease.盐皮质激素受体拮抗剂在心血管疾病中的作用。
Circ Res. 2015 Jan 2;116(1):206-13. doi: 10.1161/CIRCRESAHA.116.302706.
8
Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.螺内酯、坎利酮及其共同代谢产物坎利酮在新维度 vista LOCI 地高辛免疫分析中对地高辛的临床无显著负干扰。
J Clin Lab Anal. 2012 May;26(3):143-7. doi: 10.1002/jcla.21501.
9
Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.儿童患者静脉给予坎利酮钾后坎利酮的群体药代动力学模型。
Br J Clin Pharmacol. 2012 Nov;74(5):864-72. doi: 10.1111/j.1365-2125.2012.04257.x.
10
Canrenone--the principal active metabolite of spironolactone?坎利酮——螺内酯的主要活性代谢物？
Br J Clin Pharmacol. 1976 Aug;3(4):607-12. doi: 10.1111/j.1365-2125.1976.tb04883.x.